Redx Pharma (REDX) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Jun 2024 10:39 AM
EQS
Redx Reports Encouraging Zamaporvint (RXC004)...
01 May 2024 07:00 AM
RNS
Cancellation - Redx Pharma Plc
30 Apr 2024 05:46 PM
RNS
Share Purchases by a PDMR
30 Apr 2024 07:00 AM
RNS
Share Purchases by PDMR’s
29 Apr 2024 07:00 AM
RNS
Update on AIM Delisting
22 Apr 2024 05:45 PM
RNS
TR-1: Notification of major holdings
19 Apr 2024 12:18 PM
RNS
Result of GM, Cancellation of Admission to Trading
18 Apr 2024 07:00 AM
RNS
Share Purchases by a Director
12 Apr 2024 07:00 AM
RNS
Share Purchase by a Director
10 Apr 2024 07:00 AM
RNS
Update on Broking Arrangements
08 Apr 2024 03:32 PM
RNS
TR-1: Notification of major holdings
02 Apr 2024 07:00 AM
RNS
Proposed Cancellation of Admission to Trading
14 Mar 2024 11:27 AM
RNS
Result of AGM
06 Mar 2024 07:00 AM
RNS
Redx to Exhibit Three Posters at AACR
28 Feb 2024 07:00 AM
RNS
First Participant Dosed in Phase 1 Trial of RXC008
26 Feb 2024 07:00 AM
RNS
Redx to Present at Cowen Health Care Conference
23 Feb 2024 07:00 AM
RNS
New Grant of Options
16 Feb 2024 04:50 PM
RNS
Notice of AGM
14 Feb 2024 07:00 AM
RNS
Statement re Press Report
08 Feb 2024 01:02 PM
RNS
TR-1: Notification of major holdings
07 Feb 2024 07:00 AM
RNS
Redx announces sale of KRAS inhibitor program
15 Dec 2023 07:00 AM
RNS
Final Audited Results for Year Ended 30 September
12 Dec 2023 07:00 AM
RNS
Notice of Preliminary Results
09 Nov 2023 07:00 AM
RNS
Holdings in Company
08 Nov 2023 01:58 PM
RNS
TR-1: Notification of major holdings
08 Nov 2023 01:55 PM
RNS
TR-1: Notification of major holdings
07 Nov 2023 08:10 AM
RNS
Admission of Subscription Shares and TVR
06 Nov 2023 11:22 AM
RNS
Results of General Meeting
06 Nov 2023 07:00 AM
RNS
Redx Unveils Preclinical Data from RXC009
30 Oct 2023 07:00 AM
RNS
Redx to present preclinical data on RXC009 at ASN
18 Oct 2023 07:00 AM
RNS
Proposed Subscription to raise c.£14.1 million
06 Sep 2023 10:45 AM
RNS
Confirmation of Directorate Change
22 Aug 2023 07:00 AM
RNS
Directorate Change
21 Aug 2023 07:00 AM
RNS
Zelasudil granted FDA Orphan Drug Designation
10 Jul 2023 07:00 AM
RNS
Extension to Termination of Convertible Loan Notes
03 Jul 2023 07:00 AM
RNS
Directorate Change
30 Jun 2023 07:00 AM
RNS
New Grant of Options
31 May 2023 07:00 AM
RNS
Redx to present at Jefferies Healthcare Conference
17 May 2023 07:00 AM
RNS
Interim Results for the Six Months Ended 31 March
12 May 2023 09:51 AM
RNS
Discovery of Pirtobrutinib Recognised with Plaque
11 May 2023 07:00 AM
RNS
Presentation of RXC007 Preclinical Efficacy Data
10 May 2023 07:00 AM
RNS
Notice of Interim Results
03 May 2023 07:00 AM
RNS
Redx to Present at Keystone Symposia
03 Apr 2023 07:01 AM
RNS
Proposed Business Combination Formally Lapsed
27 Mar 2023 02:06 PM
RNS
Statement Following Jounce Announcement
15 Mar 2023 04:40 PM
RNS
Second Price Monitoring Extn
15 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
15 Mar 2023 02:05 PM
RNS
Second Price Monitoring Extn
15 Mar 2023 02:00 PM
RNS
Price Monitoring Extension
15 Mar 2023 10:50 AM
RNS
Statement re: Jounce Therapeutics Press Release
UK 100

Latest directors dealings